Deciphering the pharmacological paradox: mechanism mismatch and stratification inadequacies in herbal–NSAID combination therapy
Year: 2026
Type: article
Abstract: Dear Editor, We read with great interest the multicenter prospective cohort study by Wang and colleagues evaluating the real-world comparative effectiveness of the herbal Gutong patch (GTP), oral NSAIDs, and their combinations in patients with soft tissue injuries[1]. In this 35-center cohort (n = 1378), GTP monotherapy achieved intermediate analgesic efficacy – better than non-selective COX inhibitors (NSCI) and GTP + NSCI, and numerically lower in analgesic improvement than selective COX-2 inhibitors (SCIs) and GTP + SCI – while showing low short-term adverse-event rates and good overall tolerability within the 14-day follow-up window, without the longer-term gastrointestinal and cardiovascular concerns associated with systemic NSAIDs[1]. Notably, none of the GTP–NSAID combinations demonstrated convincing therapeutic synergy across pain, function, or quality-of-life outcomes. Several numerical details make these observations particularly informative. The therapeutic arms were well populated (GTP: n = 471, SCI: n = 254, NSCI: n = 244, GTP + SCI: n = 205, GTP + NSCI: n = 204). Median time to joint motion recovery was 1 day in the GTP group [interquartile range (IQR) 1–5], compared with 2 days in the SCI group, 5 days in the NSCI group, and 4 days in the GTP + NSCI group. Complete pain disappearance by day 14 ranged from approximately 38% to 71% across groups, again without a clear added benefit of any combination strategy[1]. The discussion appropriately considers expectation bias and the thermogenic properties of the patch as potential contributors to these findings[1]. The data also fit a broader hypothesis of pharmacological mismatch between these modalities. NSAIDs act primarily through cyclooxygenase (COX) inhibition and subsequent suppression of prostaglandin synthesis[2], which in turn can blunt prostaglandin-mediated vasodilation and local hyperemia. In contrast, key GTP constituents such as chili and cinnamon oil are included in the current patch formulation[3]. In traditional practice, such “warming” botanicals are regarded as promoting vasodilation, mild neurogenic inflammation, and increased metabolic turnover – a profile closer to “pro-resolution” or “blood-activating” modulation than simple anti-inflammation. When these opposing forces on microcirculation and inflammatory dynamics are applied simultaneously, they may blunt each other’s benefits and create a functional stalemate in the injury microenvironment. The real-world design is a major strength, but the broad definition of “soft tissue injury” inevitably aggregates pathophysiologically distinct entities. Acute ligamentous sprains, with vascular disruption and early neutrophil influx, differ markedly from chronic myofascial pain or repetitive muscle strain dominated by ischemia, fibrosis, and nociceptor sensitization[4,5]. Baseline heterogeneity in age, comorbidities, pain “temperature” patterns, and physical examination findings – such as higher comorbidity rates in the SCI group (41.7%) and more frequent cold-type pain in the GTP + NSCI group (23.0%) – further illustrates that multiple biological phenotypes are represented[1]. We therefore encourage exploratory stratified analyses along two dimensions that are already available in the dataset. First, temporal stratification by chronicity (e.g., <48 hours, 2–7 days, and >1 week from injury) could clarify whether GTP is better suited as a subacute or remodeling-phase therapy rather than as a first-line option in the hyper-acute setting. Second, stratification by dominant tissue type (muscle versus tendon or ligament versus fascia) may reveal whether the warming, vasodilatory, and blood-activating profile of GTP confer particular benefit in more ischemic or fibrotic lesions. Another key issue is outcome measurement. The current use of VAS, EQ-5D-3L, and SF-36 is appropriate for capturing patient-reported pain and function, and the large sample provides robust estimates of real-world effectiveness[1]. Yet subjective scales alone cannot differentiate structural healing from altered pain perception. The tactile presence of the patch, proprioceptive feedback akin to taping, and counter-irritant warmth may all contribute to analgesia independently of actual tissue repair, potentially by engaging placebo-like top-down modulation of pain as recently delineated in experimental models[6]. We suggest that future mechanistic studies incorporate objective biomarkers – such as shear-wave elastography for muscle stiffness, infrared thermography for local perfusion, and serum markers including IL-6[7] and prostaglandin E2[8] – to complement, rather than replace, the patient-reported outcomes that anchor this important cohort. In summary, Wang et al provide real-world evidence that challenges the intuitive assumption of automatic additive efficacy when combining pharmacologically disparate analgesic modalities[1]. Their data suggest that, for soft tissue injury, well-chosen monotherapy may be preferable to empiric combination therapy, particularly when treatment is aligned with the phase and pathophysiology of the lesion. Clarifying the mechanistic compatibility of GTP with NSAIDs and defining the optimal temporal window and target phenotypes for patch-based therapy will be crucial for integrating traditional transdermal formulations into precision orthopedic and sports-medicine practice. We commend the authors for their rigorous work and hope that these suggestions encourage additional analyses that further increase the translational impact of their study.
Source: International Journal of Surgery
Authors: Jiayuan Huang, Baodong Wang, Qiang Zhan
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,450
OpenAlex ID: W7119523471